Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXL065 in NASH (DESTINY-1)
NCT04321343Phase 2Completed
- Sponsor
- Poxel SA
- Start
- Sep 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pxl065 in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Poxel SA. Primary endpoint: Relative Change From Baseline to Week 36 in the Percentage of Liver Fat Content (LFC). Started Sep 2020; status: completed.
02
Drugs
pxl065
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04321343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321343.